Genedrive PLC
14 July 2026
14 July 2026
genedrive plc
("genedrive" or the "Company")
Board Appointment
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that Mr. Graham Cole CBE has joined the Board as Chair and an independent Non-Executive Director with immediate effect.
Graham brings more than four decades of UK and international leadership, board and governance experience across commercial businesses in the advanced engineering, manufacturing and technology sectors. He previously served as Chairman of Westland Helicopters responsible for annual revenues worldwide of around £4 billion and held a number of senior executive positions within the AgustaWestland Group, including Managing Director with responsibility for global operations. He also served on the Board of parent company Finmeccanica UK and has extensive experience of working with investors, UK Government, industry and commercial stakeholders.
In addition to his executive career, Graham has held several non-executive and advisory positions. He has also served on several UK Government ministerial committees, was appointed a CBE in 2004 for services to the aerospace industry, and holds Freedom to the City of London, and in 2008 he was awarded the Commendatore dell' Ordine della Stella della Solidarietà Italiana by the President of Italy for his work on Anglo Italian business.
The Board process to appoint two further independent Non-Executive Directors is ongoing and further announcements will be made in due course.
Dr Gino Miele, CEO of genedrive plc, said: "On behalf of the Board, I am delighted to welcome Graham to genedrive. He brings extensive international commercial experience, a high-quality network, and a strong track record of leading international businesses through commercial operations and growth. As we continue to accelerate the adoption of our pharmacogenetic tests in the UK and internationally, Graham's strategic expertise and guidance will be integral to the Board, and we look forward to working with him."
Mr Graham Cole CBE, Chairman of genedrive plc, said: "genedrive has developed innovative pharmacogenetic tests that address important clinical needs that have the potential to make a real difference for patients and deliver value to healthcare systems. The Company has reached an important stage in its development, with growing commercial opportunities in the UK and internationally. I look forward to working with the Board and the wider team to build on that progress, execute the growth strategy, unlock genedrive's long-term potential, and create value for shareholders."
Additional Information on Graham Cole
The following additional information is provided with regards to the appointment of Graham Nigel Cole CBE, aged 77, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies:
|
|
|
|
Current directorships/partnerships: |
Former directorships/partnerships (within the last five years): |
|
Agile Spray Response Limited |
Elleston Services Limited |
|
GNC Associated Limited |
Portman Place Sherborne Management Company Limited |
|
Reconnaissance Ventures Limited |
|
|
SSDC Business Solutions |
|
Graham Cole does not hold any ordinary shares in the Company.
There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
|
genedrive plc |
+44 (0)161 989 0245 |
|
Gino Miele: CEO / Russ Shaw: CFO |
|
|
Peel Hunt LLP (Nominated Adviser and Broker) |
+44 (0)20 7418 8900 |
|
James Steel |
|
|
5654 & Company (Media & Investor Relations) |
genedrive@5654.co.uk |
|
Matthew Neal |
+44 (0)7917 800 011 |
|
Melissa Gardiner |
+44 (0)7757 697357 |
Subscribe to our news alert service: https://investors.genedrive.com/s/efea03
About genedrive plc (http://www.genedrive.com).
genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.
genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention
The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.
Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.